These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

373 related articles for article (PubMed ID: 33722907)

  • 1. Natural killer T cell immunotherapy combined with oncolytic vesicular stomatitis virus or reovirus treatments differentially increases survival in mouse models of ovarian and breast cancer metastasis.
    Gebremeskel S; Nelson A; Walker B; Oliphant T; Lobert L; Mahoney D; Johnston B
    J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33722907
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Fusogenic vesicular stomatitis virus combined with natural killer T cell immunotherapy controls metastatic breast cancer.
    Nelson A; McMullen N; Gebremeskel S; De Antueno R; Mackenzie D; Duncan R; Johnston B
    Breast Cancer Res; 2024 May; 26(1):78. PubMed ID: 38750591
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Natural killer T cell immunotherapy combined with IL-15-expressing oncolytic virotherapy and PD-1 blockade mediates pancreatic tumor regression.
    Nelson A; Gebremeskel S; Lichty BD; Johnston B
    J Immunother Cancer; 2022 Mar; 10(3):. PubMed ID: 35246474
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Natural Killer T-cell Immunotherapy in Combination with Chemotherapy-Induced Immunogenic Cell Death Targets Metastatic Breast Cancer.
    Gebremeskel S; Lobert L; Tanner K; Walker B; Oliphant T; Clarke LE; Dellaire G; Johnston B
    Cancer Immunol Res; 2017 Dec; 5(12):1086-1097. PubMed ID: 29054890
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prime-boost using separate oncolytic viruses in combination with checkpoint blockade improves anti-tumour therapy.
    Ilett E; Kottke T; Thompson J; Rajani K; Zaidi S; Evgin L; Coffey M; Ralph C; Diaz R; Pandha H; Harrington K; Selby P; Bram R; Melcher A; Vile R
    Gene Ther; 2017 Jan; 24(1):21-30. PubMed ID: 27779616
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Reovirus-induced cell-mediated immunity for the treatment of multiple myeloma within the resistant bone marrow niche.
    Müller LME; Migneco G; Scott GB; Down J; King S; Askar B; Jennings V; Oyajobi B; Scott K; West E; Ralph C; Samson A; Ilett EJ; Muthana M; Coffey M; Melcher A; Parrish C; Cook G; Lawson M; Errington-Mais F
    J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33741729
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The strength of the T cell response against a surrogate tumor antigen induced by oncolytic VSV therapy does not correlate with tumor control.
    Janelle V; Langlois MP; Lapierre P; Charpentier T; Poliquin L; Lamarre A
    Mol Ther; 2014 Jun; 22(6):1198-1210. PubMed ID: 24590047
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immune Effects of M51R Vesicular Stomatitis Virus Treatment of Carcinomatosis From Colon Cancer.
    Day GL; Bryan ML; Northrup SA; Lyles DS; Westcott MM; Stewart JH
    J Surg Res; 2020 Jan; 245():127-135. PubMed ID: 31415934
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Reovirus FAST Protein Enhances Vesicular Stomatitis Virus Oncolytic Virotherapy in Primary and Metastatic Tumor Models.
    Le Boeuf F; Gebremeskel S; McMullen N; He H; Greenshields AL; Hoskin DW; Bell JC; Johnston B; Pan C; Duncan R
    Mol Ther Oncolytics; 2017 Sep; 6():80-89. PubMed ID: 28856238
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Multifaceted therapeutic targeting of ovarian peritoneal carcinomatosis through virus-induced immunomodulation.
    Gujar S; Dielschneider R; Clements D; Helson E; Shmulevitz M; Marcato P; Pan D; Pan LZ; Ahn DG; Alawadhi A; Lee PW
    Mol Ther; 2013 Feb; 21(2):338-47. PubMed ID: 23299799
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Repurposing Sunitinib with Oncolytic Reovirus as a Novel Immunotherapeutic Strategy for Renal Cell Carcinoma.
    Lawson KA; Mostafa AA; Shi ZQ; Spurrell J; Chen W; Kawakami J; Gratton K; Thakur S; Morris DG
    Clin Cancer Res; 2016 Dec; 22(23):5839-5850. PubMed ID: 27220962
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The efficacy versus toxicity profile of combination virotherapy and TLR immunotherapy highlights the danger of administering TLR agonists to oncolytic virus-treated mice.
    Rommelfanger DM; Compte M; Grau MC; Diaz RM; Ilett E; Alvarez-Vallina L; Thompson JM; Kottke TJ; Melcher A; Vile RG
    Mol Ther; 2013 Feb; 21(2):348-57. PubMed ID: 23011032
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Susceptibility of breast cancer cells to an oncolytic matrix (M) protein mutant of vesicular stomatitis virus.
    Ahmed M; Puckett S; Lyles DS
    Cancer Gene Ther; 2010 Dec; 17(12):883-92. PubMed ID: 20725101
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pre-surgical neoadjuvant oncolytic virotherapy confers protection against rechallenge in a murine model of breast cancer.
    Martin NT; Roy DG; Workenhe ST; van den Wollenberg DJM; Hoeben RC; Mossman KL; Bell JC; Bourgeois-Daigneault MC
    Sci Rep; 2019 Feb; 9(1):1865. PubMed ID: 30755678
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lymphokine-activated killer and dendritic cell carriage enhances oncolytic reovirus therapy for ovarian cancer by overcoming antibody neutralization in ascites.
    Jennings VA; Ilett EJ; Scott KJ; West EJ; Vile R; Pandha H; Harrington K; Young A; Hall GD; Coffey M; Selby P; Errington-Mais F; Melcher AA
    Int J Cancer; 2014 Mar; 134(5):1091-101. PubMed ID: 23982804
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Vesicular Stomatitis Virus (VSV) G Glycoprotein Can Be Modified to Create a Her2/Neu-Targeted VSV That Eliminates Large Implanted Mammary Tumors.
    Gao Y; Bergman I
    J Virol; 2023 Jun; 97(6):e0037223. PubMed ID: 37199666
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Interference of CD40L-mediated tumor immunotherapy by oncolytic vesicular stomatitis virus.
    Galivo F; Diaz RM; Thanarajasingam U; Jevremovic D; Wongthida P; Thompson J; Kottke T; Barber GN; Melcher A; Vile RG
    Hum Gene Ther; 2010 Apr; 21(4):439-50. PubMed ID: 19922169
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Gemcitabine enhances the efficacy of reovirus-based oncotherapy through anti-tumour immunological mechanisms.
    Gujar SA; Clements D; Dielschneider R; Helson E; Marcato P; Lee PW
    Br J Cancer; 2014 Jan; 110(1):83-93. PubMed ID: 24281006
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dendritic cells and T cells deliver oncolytic reovirus for tumour killing despite pre-existing anti-viral immunity.
    Ilett EJ; Prestwich RJ; Kottke T; Errington F; Thompson JM; Harrington KJ; Pandha HS; Coffey M; Selby PJ; Vile RG; Melcher AA
    Gene Ther; 2009 May; 16(5):689-99. PubMed ID: 19282847
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Loading of oncolytic vesicular stomatitis virus onto antigen-specific T cells enhances the efficacy of adoptive T-cell therapy of tumors.
    Qiao J; Wang H; Kottke T; Diaz RM; Willmon C; Hudacek A; Thompson J; Parato K; Bell J; Naik J; Chester J; Selby P; Harrington K; Melcher A; Vile RG
    Gene Ther; 2008 Apr; 15(8):604-16. PubMed ID: 18305577
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.